Abstract 119P
Background
Waiting for the highest pCR is clinically relevant as this helps to choose the candidates for a watch–and–wait approach or local excision, identify the optimal operation timing, increase the chance of R0 resection, or improve disease–free survival and/or overall survival. Meanwhile, LR is a serious problem since it causes disabling symptoms, and successful salvage of pelvic recurrence is rarely possible. Therefore, this paper will investigate the impacts of dose fractionations of preoperative radiotherapy (RT) on pCR and LR for rectal cancer using three– or four–field conformal RT techniques.
Methods
The PubMed, Embase, and Web of Science databases (2000 to May 2018) were systematically searched for evidence. To evaluate the dose–response relationship, logistic response curves were fitted for pCR values, and the linear regression model was fitted for risk reduction of LR as a function of biologic effective dose (BED).
Results
Data from 8 comparative studies enrolling 14,869 patients were analyzed for pCR. Higher radiation doses were associated with increased pCR. If pCR curve was fitted using BED as a covariate, the dose required for 50% response (D50) ranged from 68·3 to 108·0 Gy. If BED was corrected with RT overall treatment time, The pCR curves of the similar treatment regimens in special patient cohorts interacted at identical D50, 50.7, 59.0, or 70.9 Gy. Regarding LR risk, 31 studies were identified and yielded 7,699 patients. Increasing RT doses was also associated with reduction in LR, and a linear dose–response effect of BED was seen on the risk reduction of LR. Each 1 Gy increase in BED would reduce LR by 1·36%, hence a hypothesis was proposed that a BED of approximately 73.5 Gy would need to achieve 100% LC.
Conclusions
Higher radiation doses were associated with increased pCR and LR reduction. In the future, by means of dose–response curves and the available pCR and LR values, we could perhaps obtain the dose gap to achieve 50% pCR response and 100% LC, and predict the amplitude of clinical benefits through limited RT dose escalation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract